Targeting mitochondrial quality control: Ginsenoside Rg1 as a therapeutic candidate for neuromuscular diseases

IF 7.5 2区医学 Q1 CHEMISTRY, MEDICINAL

Journal of Ginseng Research Pub Date : 2026-03-01 Epub Date: 2025-12-12 DOI:10.1016/j.jgr.2025.12.003

Xiaoqing Cai , Haixia Lan , Yingying Jiao , Yaoqi Wu , Peidan Yang , Tongkai Chen , Yafang Song

{"title":"Targeting mitochondrial quality control: Ginsenoside Rg1 as a therapeutic candidate for neuromuscular diseases","authors":"Xiaoqing Cai , Haixia Lan , Yingying Jiao , Yaoqi Wu , Peidan Yang , Tongkai Chen , Yafang Song","doi":"10.1016/j.jgr.2025.12.003","DOIUrl":null,"url":null,"abstract":"<div><div>Neuromuscular diseases (NMDs) are complex disorders caused by the dysfunction of motor neurons and skeletal muscles. They lead to progressive muscle weakness and atrophy and impose a significant economic burden on patients and society at large. The dysregulation of mitochondrial quality control (MQC), a key cellular process, contributes to the pathogenesis of several NMDs. Interestingly, accumulating evidence demonstrates that ginsenoside Rg1 can regulate MQC by modulating mitochondrial dynamics, mitophagy, mitochondrial biogenesis, and mitocytosis, thus aiding with the management of several diseases. This review comprehensively summarizes the current understanding of ginsenoside Rg1's effects on mitochondrial function. Furthermore, it proposes that Rg1 may target MQC mechanisms, emerging as an effective active agent for the treatment of NMDs. This review aims to bridge existing knowledge gaps and establish a theoretical foundation for the clinical application of ginsenoside Rg1 in the treatment of NMDs characterized by MQC dysfunction.</div></div>","PeriodicalId":16035,"journal":{"name":"Journal of Ginseng Research","volume":"50 2","pages":"Article 100930"},"PeriodicalIF":7.5000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ginseng Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1226845325001824","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Neuromuscular diseases (NMDs) are complex disorders caused by the dysfunction of motor neurons and skeletal muscles. They lead to progressive muscle weakness and atrophy and impose a significant economic burden on patients and society at large. The dysregulation of mitochondrial quality control (MQC), a key cellular process, contributes to the pathogenesis of several NMDs. Interestingly, accumulating evidence demonstrates that ginsenoside Rg1 can regulate MQC by modulating mitochondrial dynamics, mitophagy, mitochondrial biogenesis, and mitocytosis, thus aiding with the management of several diseases. This review comprehensively summarizes the current understanding of ginsenoside Rg1's effects on mitochondrial function. Furthermore, it proposes that Rg1 may target MQC mechanisms, emerging as an effective active agent for the treatment of NMDs. This review aims to bridge existing knowledge gaps and establish a theoretical foundation for the clinical application of ginsenoside Rg1 in the treatment of NMDs characterized by MQC dysfunction.

Abstract Image

查看原文本刊更多论文

靶向线粒体质量控制：人参皂苷Rg1作为神经肌肉疾病的候选治疗药物。

神经肌肉疾病是由运动神经元和骨骼肌功能障碍引起的复杂疾病。它们会导致进行性肌肉无力和萎缩，给患者和整个社会造成重大的经济负担。线粒体质量控制（MQC）是一个关键的细胞过程，其失调与几种nmd的发病机制有关。有趣的是，越来越多的证据表明，人参皂苷Rg1可以通过调节线粒体动力学、线粒体自噬、线粒体生物发生和有丝分裂来调节MQC，从而有助于治疗多种疾病。本文综述了目前对人参皂苷Rg1对线粒体功能影响的研究进展。此外，这表明Rg1可能靶向MQC机制，成为治疗nmd的有效活性剂。本文旨在弥补现有的知识空白，为人参皂苷Rg1治疗MQC功能障碍为特征的nmd的临床应用奠定理论基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Ginseng Research CHEMISTRY, MEDICINAL-INTEGRATIVE & COMPLEMENTARY MEDICINE

CiteScore

11.40

自引率

9.50%

发文量

111

审稿时长

6-12 weeks

期刊介绍： Journal of Ginseng Research (JGR) is an official, open access journal of the Korean Society of Ginseng and is the only international journal publishing scholarly reports on ginseng research in the world. The journal is a bimonthly peer-reviewed publication featuring high-quality studies related to basic, pre-clinical, and clinical researches on ginseng to reflect recent progresses in ginseng research. JGR publishes papers, either experimental or theoretical, that advance our understanding of ginseng science, including plant sciences, biology, chemistry, pharmacology, toxicology, pharmacokinetics, veterinary medicine, biochemistry, manufacture, and clinical study of ginseng since 1976. It also includes the new paradigm of integrative research, covering alternative medicinal approaches. Article types considered for publication include review articles, original research articles, and brief reports. JGR helps researchers to understand mechanisms for traditional efficacy of ginseng and to put their clinical evidence together. It provides balanced information on basic science and clinical applications to researchers, manufacturers, practitioners, teachers, scholars, and medical doctors.